The forecast for the re-import of antisera and other blood fractions to France suggests a consistent annual decline. Starting from 1.71 thousand kilograms in 2024, the values are expected to decrease to 1.15 thousand kilograms by 2028. From 2024 onwards, the annual reduction averages approximately 8.9% per year. This declining trend indicates a significantly shrinking market compared to recent years, with the forecast in 2024 standing equivalent to the previous year, 2023.
Future trends to watch for include:
- Potential advancements in domestic production capabilities in France that may reduce the need for imports.
- Regulatory changes impacting the importation of biomedical products.
- The development of alternative biomedical products which could influence demand.
